...

Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

This is a first-in-human study to learn about the study drug called BG-C9074 alone and in combination with tislelizumab in participants with advanced solid tumors.

Why this Research Matters

The study drug called BG-C9075 will be given alone and in combination with tislelizumab in participants with advanced solid tumors.

Who can Participate

Adult

Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.

Study ID

Protocol Number: 24-1128
More information available at ClinicalTrials.gov: NCT06233942

Meet the Team

Image of Principal Investigator

Jennifer Diamond, MD

Principal Investigator

Categories

Locations